Abstract
Histone deacetylases (HDACs) are a family of conserved metalloproteases which play a key role in the development of cancer. They can be divided into 18 subtypes according to their structural diversity. Histone deacetylase inhibitors are considered as potential anti-cancer agents and a lot of pan-HDAC inhibitors have entered clinical trials. Selective HDAC inhibitors targeting only one member or one class subtype are less exploited at present and regarded less toxic as well as more tolerable than pan-HDAC inhibitors. Certain structural modifications or new moieties may help to acquire isoform selectivity. In this review, we will focus on each member of HDACs and selective HDAC inhibitors as well as the relationship between structure and selectivity.
Keywords: HDAC, Histone deacetylase inhibitors, Selectivity, Anti-cancer agents, aminobenzamides, cyclic peptides, yeast HDACs, C-terminus, bone homeostasis, Sirtuins
Anti-Cancer Agents in Medicinal Chemistry
Title: Selective Histone Deacetylase Inhibitors
Volume: 12 Issue: 3
Author(s): Huili Pan, Jiangying Cao and Wenfang Xu
Affiliation:
Keywords: HDAC, Histone deacetylase inhibitors, Selectivity, Anti-cancer agents, aminobenzamides, cyclic peptides, yeast HDACs, C-terminus, bone homeostasis, Sirtuins
Abstract: Histone deacetylases (HDACs) are a family of conserved metalloproteases which play a key role in the development of cancer. They can be divided into 18 subtypes according to their structural diversity. Histone deacetylase inhibitors are considered as potential anti-cancer agents and a lot of pan-HDAC inhibitors have entered clinical trials. Selective HDAC inhibitors targeting only one member or one class subtype are less exploited at present and regarded less toxic as well as more tolerable than pan-HDAC inhibitors. Certain structural modifications or new moieties may help to acquire isoform selectivity. In this review, we will focus on each member of HDACs and selective HDAC inhibitors as well as the relationship between structure and selectivity.
Export Options
About this article
Cite this article as:
Pan Huili, Cao Jiangying and Xu Wenfang, Selective Histone Deacetylase Inhibitors, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (3) . https://dx.doi.org/10.2174/187152012800228814
DOI https://dx.doi.org/10.2174/187152012800228814 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemotherapy for Prostate Cancer
Current Pharmaceutical Design Isoprenylation of Intracellular Proteins as a New Target for the Therapy of Human Neoplasms: Preclinical and Clinical Implications
Current Drug Targets Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design Proteomic Analysis of Cerebrospinal Fluid: A Search for Biomarkers of Neuropsychiatric Systemic Lupus Erythematosus
Current Proteomics Inhibitors of the Chemokine Receptor CXCR4: Chemotherapy of AIDS, Metastatic Cancer, Leukemia and Rheumatoid Arthritis
Letters in Drug Design & Discovery A Comparison of the Inhibitory Effects of Anti-Cancer Drugs on Thioredoxin Reductase and Glutathione S-Transferase in Rat Liver
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs in Non-small Cell Lung Cancer: Current Status and Future Therapeutic Promises
Current Pharmaceutical Design Regulation of the DNA Damage Response to DSBs by Post-Translational Modifications
Current Genomics Quercetin in Cancer Treatment, Alone or in Combination with Conventional Therapeutics?
Current Medicinal Chemistry Recent Advances Using Phosphodiesterase 4 (PDE4) Inhibitors to Treat Inflammatory Disorders: Animal and Clinical Studies
Current Drug Therapy A Scientometrics Analysis and Visualization of Depressive Disorder
Current Neuropharmacology Meet Our Regional Editor
Anti-Cancer Agents in Medicinal Chemistry Polymer-Based Drug Delivery Systems, Development and Pre-Clinical Status
Current Pharmaceutical Design Targeting of NF-kappaB Signaling Pathway, other Signaling Pathways and Epigenetics in Therapy of Multiple Myeloma
Cardiovascular & Hematological Disorders-Drug Targets Regulation and Function of DNA and Histone Methylations
Current Pharmaceutical Design The Effects of Dietary Supplements that Overactivate the Nrf2/ARE System
Current Medicinal Chemistry Synthetic Curcumin Analog UBS109 Inhibits the Growth of Head and Neck Squamous Cell Carcinoma Xenografts
Current Cancer Drug Targets Body Fluids-Derived Exosomes: Paving the Novel Road to Lung Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry PEGylated Lipid Nanocapsules with Improved Drug Encapsulation and Controlled Release Properties
Current Topics in Medicinal Chemistry Challenges & Outcome of Thoracic Surgery in a Resource Constrained Developing African Country
Current Respiratory Medicine Reviews